BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS  The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing...
BC Innovations | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BC Week In Review | Oct 13, 2017
Financial News

Intezyne raises $10M in series A

On Oct. 6, Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO...
BC Extra | Oct 6, 2017
Financial News

Intezyne raises $10M series A

Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO E. Russell McAllister...
BC Innovations | Aug 17, 2017
Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development....
BC Innovations | Jun 22, 2017
Translation in Brief

TERS talk

A UCSD group has added "transmissible ER stress (TERS)" to the list of cancer's survival strategies. In a study published this month in Science Signaling , the group showed cancer cells undergoing ER stress send soluble...
BC Innovations | Jun 14, 2017
Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Mouse studies suggest inhibiting HspA5 could help treat pancreatic ductal adenocarcinoma (PDAC). In male and female mouse models of PDAC, HspA5 knockdown decreased number of ducts with acinar-to-ductal metaplasia, Pancreatic Intraepithelial Neoplasias...
BC Innovations | Nov 15, 2016
Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains An HspA5 -targeting AAVP could be used to deliver gene therapies for aggressive breast cancer. The particle consisted of an AAVP particle engineered to express a peptide that binds HspA5, a protein...
BC Innovations | Jun 2, 2016
Distillery Therapeutics

Therapeutics: Heat shock 70 kDa protein 5 (glucose-regulated protein, 78kDa) (HspA5; GRP78)

Cancer INDICATION: Cancer; leukemia; melanoma In vitro, cell culture and mouse studies identified a thiazole-based HspA5 inhibitor that could help treat drug-resistant melanoma and other cancers. Chemical synthesis and in vitro testing of thiazole analogs...
BC Innovations | Apr 2, 2015
Distillery Techniques

Techniques: Peptide ligands for tumor-expressed α-2-macroglobulin (A2M) and heat shock 70 kDa protein 5 (glucose-regulated protein, 78kDa) (HspA5; GRP78)

Drug delivery TECHNOLOGY: Targeting domains Mouse studies identified tumor-homing peptides that could help target therapies to metastatic prostate cancers. In a xenograft mouse model of prostate cancer that metastasized to the bone, phage display on...
Items per page:
1 - 10 of 31